Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 2
2006 1
2007 2
2008 1
2009 3
2010 5
2011 2
2012 7
2013 6
2014 8
2015 13
2016 16
2017 11
2018 18
2019 15
2020 20
2021 19
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: kuwata t. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: kuwata t. Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31. Nat Immunol. 2020. PMID: 32868929
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Fukuoka S, et al. Among authors: kuwata t. J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343640 Clinical Trial.
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: kuwata t. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M, Sakamoto N, Kojima M, Kuwata T, Yoshino T, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Takei S, et al. Among authors: kuwata t. J Immunother Cancer. 2024 Feb 8;12(2):e008210. doi: 10.1136/jitc-2023-008210. J Immunother Cancer. 2024. PMID: 38336371 Free PMC article.
Guidelines for Handling of Cytological Specimens in Cancer Genomic Medicine.
Morii E, Hatanaka Y, Motoi N, Kawahara A, Hamakawa S, Kuwata T, Nagatomo T, Oda Y, Okamoto A, Tanaka R, Iyoda A, Ichiro M, Matsuo Y, Nakamura N, Nakai T, Fukuhara M, Tokita K, Yamaguchi T, Takenaka M, Kawabata A, Hatanaka KC, Tsubame K, Satoh Y; Working Group on Cytology in the Era of Genomic Medicine. Morii E, et al. Among authors: kuwata t. Pathobiology. 2023;90(5):289-311. doi: 10.1159/000528346. Epub 2023 Feb 8. Pathobiology. 2023. PMID: 36754025 Free PMC article. Review.
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.
Chida K, Kawazoe A, Suzuki T, Kawazu M, Ueno T, Takenouchi K, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Kuwata T, Sakamoto N, Watanabe J, Mano H, Ikeda M, Shitara K, Endo I, Nakatsura T, Yoshino T. Chida K, et al. Among authors: kuwata t. Clin Cancer Res. 2022 May 13;28(10):2110-2117. doi: 10.1158/1078-0432.CCR-22-0041. Clin Cancer Res. 2022. PMID: 35254400 Free PMC article.
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: kuwata t. Immunity. 2020 Jul 14;53(1):187-203.e8. doi: 10.1016/j.immuni.2020.06.016. Epub 2020 Jul 7. Immunity. 2020. PMID: 32640259 Free article.
143 results